U.S. Markets close in 6 hrs 6 mins

FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%

Zacks Equity Research

FibroGen, Inc. FGEN was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $41.72–$48.45 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen four negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

FibroGen currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.

FibroGen, Inc Price

FibroGen, Inc Price

FibroGen, Inc price | FibroGen, Inc Quote

Investors interested in the Medical – Drugs industry may consider Galectin Therapeutics, Inc. GALT, which has a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Is FGEN going up? Or down? Predict to see what others think: Up or Down

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
FibroGen, Inc (FGEN) : Free Stock Analysis Report
 
Galectin Therapeutics Inc. (GALT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research